Structure-Activity Relationship of 4,6-Disubstituted Pyrimidines as EGFR and VEGFR-2 Tyrosine Kinase Inhibitors

被引：2
作者：
Song, Jiho [1 ]
Lee, Jung Wook [1 ]
Chung, Shin Hyuck [1 ]
Wenas, Michelle A. [1 ]
Min, Kyung Hoon [1 ]
机构：
[1] Chung Ang Univ, Coll Pharm, Seoul 06974, South Korea
来源：
BULLETIN OF THE KOREAN CHEMICAL SOCIETY | 2017年 / 38卷 / 11期
基金：
新加坡国家研究基金会;
关键词：
EGFR; VEGFR-2; Tyrosine kinase inhibitors; Pyrimidine; GROWTH-FACTOR RECEPTOR; BEVACIZUMAB; ERLOTINIB; CANCER; RESISTANCE; THERAPY; CELL;
D O I：
10.1002/bkcs.11278
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
[No abstract available]
引用
收藏
页码：1255 / 1256
页数：2
相关论文
共 50 条
  • [41] Structure-activity Relationship Study on Therapeutically Relevant EGFR Double Mutant Inhibitors
    Fatima, Shehnaz
    Agarwal, Subhash M.
    MEDICINAL CHEMISTRY, 2020, 16 (01) : 52 - 62
  • [42] Synthesis and antitumor activity evaluation of 4,6-disubstituted quinazoline derivatives as novel PI3K inhibitors
    Hei, Yuan-Yuan
    Xin, Minhang
    Zhang, Hao
    Xie, Xiao-Xiao
    Mao, Shuai
    Zhang, San-Qi
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (18) : 4408 - 4413
  • [43] Biological evaluation of 4-aryl-1,4-dihydropyridines as VEGFR-2 kinase inhibitors
    Sun, W.
    Ma, Z.
    Yan, H.
    RUSSIAN JOURNAL OF GENERAL CHEMISTRY, 2016, 86 (12) : 2891 - 2899
  • [44] Identification of novel sulfathiazole-triazolo-chalcone hybrids as VEGFR-2/EGFR dual inhibitors with antiangiogenic activity and apoptotic induction
    Zeidan, Mohamed A.
    Othman, Dina I. A.
    Goda, Fatma E.
    Mostafa, Amany S.
    ARCHIV DER PHARMAZIE, 2024, 357 (03)
  • [45] Dual irreversible kinase inhibitors: Quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2
    Wissner, Allan
    Fraser, Heidi L.
    Ingalls, Charles L.
    Dushin, Russell G.
    Floyd, M. Brawner
    Cheung, Kinwang
    Nittoli, Thomas
    Ravi, Malini R.
    Tan, Xingzhi
    Loganzo, Frank
    BIOORGANIC & MEDICINAL CHEMISTRY, 2007, 15 (11) : 3635 - 3648
  • [46] Novel potent substituted 4-amino-2-thiopyrimidines as dual VEGFR-2 and BRAF kinase inhibitors
    Abdel-Mohsen, Heba T.
    Omar, Mohamed A.
    El Kerdawy, Ahmed M.
    Mahmoud, Abeer E. E.
    Ali, Mamdouh M.
    El Diwani, Hoda I.
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 179 : 707 - 722
  • [47] Structure activity relationships of chrysoeriol and analogs as dual c-Met and VEGFR2 tyrosine kinase inhibitors
    Lai, Shuang
    Chen, Jun-Ning
    Huang, Han-Wei
    Zhang, Xiang-Yu
    Jiang, Hai-Lun
    Li, Wei
    Wang, Peng-Liang
    Wang, Jian
    Liu, Fu-Nan
    ONCOLOGY REPORTS, 2018, 40 (03) : 1650 - 1656
  • [48] EGFR/VEGFR-2 dual inhibitor and apoptotic inducer: Design, synthesis, anticancer activity and docking study of new 2-thioxoimidazolidin-4one derivatives
    Mourad, Ahmed A. E.
    Farouk, N. A.
    El-Sayed, El-Sherbiny H.
    Mahdy, Ahmed R. E.
    LIFE SCIENCES, 2021, 277
  • [49] Cyclic Peptides as Protein Kinase Inhibitors: Structure-Activity Relationship and Molecular Modeling
    Sanner, Michel F.
    Zoghebi, Khalid
    Hanna, Samara
    Mozaffari, Saghar
    Rahighi, Simin
    Tiwari, Rakesh K.
    Parang, Keykavous
    JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2021, 61 (06) : 3015 - 3026
  • [50] Discovery of new thieno[2,3-d]pyrimidines as EGFR tyrosine kinase inhibitors for cancer treatment
    Sobh, Eman A.
    Dahab, Mohammed A.
    Elkaeed, Eslam B.
    Alsfouk, Aisha A.
    Ibrahim, Ibrahim M.
    Metwaly, Ahmed M.
    Eissa, Ibrahim H.
    FUTURE MEDICINAL CHEMISTRY, 2023, 15 (13) : 1167 - 1184
12345